Measurement of serum paraoxonase-1 activity in the evaluation of liver function

World Journal of Gastroenterology

Volumn 15, Issue 16, 2009, Pages 1929-1933

  Camps, Jordi ^a   Marsillach, Judit ^a   Joven, Jorge ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Lipoproteins; Liver cirrhosis; Liver function tests; Oxidative stress; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; LIPOLACTONASE; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ANTIOXIDANT ACTIVITY; CHRONIC LIVER DISEASE; EDITORIAL; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; FATTY ACID OXIDATION; HEPATITIS C; HUMAN; LIPID PEROXIDATION; LIVER CELL; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; HUMANS; ISOENZYMES; LIVER; LIVER DISEASES; OXIDATIVE STRESS;

EID: 67651149766     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1929     Document Type: Editorial

References (50)

1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498-507
2. Furlong CE. Paraoxonases: an historical perspective. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Dordrecht: Springer, 2008: 3-31
3. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276: 44444-44449
4. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28: 1335-1342
5. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005; 352: 37-47
6. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247
7. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37: 1304-1316
8. Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007; 115: 2055-2064
9. Marsillach J, Parra S, Ferré N, Coll B, Alonso-Villaverde C, Joven J, Camps J. Paraoxonase-1 in chronic liver diseases, neurological diseases, and HIV infection. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Dordrecht: Springer, 2008: 187-198
10. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154
11. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135
12. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842
13. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590
14. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904
15. Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006; 351: 492-498
16. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005; 44: 6371-6382
17. Aharoni A, Amitai G, Bernath K, Magdassi S, Tawfik DS. High-throughput screening of enzyme libraries: thiolactonases evolved by fluorescence-activated sorting of single cells in emulsion compartments. Chem Biol 2005; 12: 1281-1289
18. Khersonsky O, Tawfik DS. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006; 281: 7649-7656
19. Khersonsky O, Roodveldt C, Tawfik DS. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr Opin Chem Biol 2006; 10: 498-508
20. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281: 7657-7665
21. Gil F, Pla A, Gonzalvo MC, Hernandez AF, Villanueva E. Rat liver paraoxonase: subcellular distribution and characterization. Chem Biol Interact 1993; 87: 149-154
22. Gil F, Pla A, Gonzalvo MC, Hernandez AF, Villanueva E. Partial purification of paraoxonase from rat liver. Chem Biol Interact 1993; 87: 69-75
23. Huang YS, Woods L, Sultatos LG. Solubilization and purification of A-esterase from mouse hepatic microsomes. Biochem Pharmacol 1994; 48: 1273-1280
24. Rodrigo L, Gil F, Hernandez AF, Marina A, Vazquez J, Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem J 1997; 321 (Pt 3): 595-601
25. Gonzalvo MC, Gil F, Hernandez AF, Villanueva E, Pla A. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 1997; 105: 169-179
26. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001; 137: 123-137
27. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006; 26: 1021-1028
28. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006; 65: 278-290
29. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 2008; 29: 9-16
30. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-940
31. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004; 113: 1277-1287
32. Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol 2006; 21 Suppl 3: S56-S60
33. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001; 15: 1335-1349
34. Batey RG, Cao Q, Gould B. Lymphocyte-mediated liver injury in alcohol-related hepatitis. Alcohol 2002; 27: 37-41
35. Nieto N. Ethanol and fish oil induce NFkappa B transactivation of the collagen alpha2(I) promoter through lipid peroxidation-driven activation of the PKC-PI3K-Akt pathway. Hepatology 2007; 45: 1433-1445
36. Solis Herruzo JA, Garcia Ruiz I, Perez Carreras M, Munoz Yague MT. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006; 98: 844-874
37. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G847-G851
38. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, Ikeda H, Hanano S, Suehiro M, Togawa K, Yamada G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal 2004; 6: 19-24
39. Thoren F, Romero A, Lindh M, Dahlgren C, Hellstrand K. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J Leukoc Biol 2004; 76: 1180-1186
40. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005; 13: 159-163
41. Gaidukov L, Tawfik DS. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 2007; 48: 1637-1646
42. Marsillach J, Aragones G, Beltran R, Caballeria J, Pedro-Botet J, Morcillo-Suarez C, Navarro A, Joven J, Camps J. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009; 42: 91-98
43. Ferre N, Camps J, Cabre M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001; 50: 997-1000
44. Burlina A, Galzigna L. Serum arylesterase isoenzymes in chronic hepatitis. Clin Biochem 1974; 7: 202-205
45. Burlina A, Michielin E, Galzigna L. Characteristics and behaviour of arylesterase in human serum and liver. Eur J Clin Invest 1977; 7: 17-20
46. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-268
47. Ferre N, Marsillach J, Camps J, Rull A, Coll B, Tous M, Joven J. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin Chim Acta 2005; 361: 206-210
48. Marsillach J, Ferre N, Vila MC, Lligona A, Mackness B, Mackness M, Deulofeu R, Sola R, Pares A, Pedro-Botet J, Joven J, Caballeria J, Camps J. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem 2007; 40: 645-650
49. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB, Lakshman MR. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003; 52: 1287-1294
50. Xu GY, Lv GC, Chen Y, Hua YC, Zhu SM, Yang YD. Monitoring the level of serum paraoxonase 1 activity in liver transplantation patients. Hepatobiliary Pancreat Dis Int 2005; 4: 178-181